ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

autologous rapamycin-resistant TH1/TC1 cells RAPA-201

Also written as “RAPA-201 Rapamycin Resistant T Cells” and “RAPA-201 Autologous T cells”.

Its studies are mostly in Melanoma · Multiple Myeloma · Carcinoma, Non-Small-Cell Lung, led by Rapa Therapeutics.

Furthest: phase 2, since Nov 12, 20193 company-led studies, 2 open or runningNext primary completion: Mar 1, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Rapa Therapeutics32 open or runningphase 2since Nov 12, 2019Nov 12, 2019Mar 1, 2029phase 2 · NCT06708455

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 12, 2019First study: phase 2 study in RecurrenceFirst studyNCT04176380 · 15 enrolled · United States
  2. Nov 5, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05144698 · 37 planned · United States
  3. Nov 19, 2024Phase 2 study in MelanomaNCT06708455 · 65 planned · United States

Ahead

  1. Mar 1, 2029Primary completion: phase 2 study in MelanomaNCT06708455

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06708455Melanoma · United States2Not yet recruitingMar 1, 202965
NCT05144698Carcinoma, Non-Small-Cell Lung · United States2RecruitingJan 1, 202637
NCT04176380Recurrence · United States2CompletedJan 30, 202315

How it is read

Names in the registry

  • “RAPA-201 Rapamycin Resistant T Cells”, 2 entries
  • “RAPA-201 Autologous T cells”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.